Key terms
About FOLD
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FOLD news
Mar 18
7:13am ET
Amicus price target lowered to $19 from $21 at JPMorgan
Mar 06
6:19am ET
Amicus’s Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones
Mar 01
5:21am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)
Mar 01
1:04am ET
Buy Rating Affirmed: Amicus’s Strong Product Launch and Growth Trajectory
Feb 29
5:40am ET
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), TG Therapeutics (TGTX) and Amicus (FOLD)
Feb 29
5:29am ET
Needham Sticks to Its Hold Rating for Amicus (FOLD)
Feb 28
3:15pm ET
Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook
Feb 28
7:07am ET
Amicus reports Q4 EPS 1c, consensus (6c)
Jan 09
8:28am ET
Needham Sticks to Their Hold Rating for Amicus (FOLD)
Jan 09
6:40am ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Danaher (DHR) and Amicus (FOLD)
Jan 09
6:40am ET
Amicus (FOLD) Receives a Buy from TD Cowen
Jan 09
12:59am ET
Leerink Partners Sticks to Its Buy Rating for Amicus (FOLD)
Jan 08
5:33am ET
Amicus’ (NASDAQ:FOLD) 2023 Sales Exceed Expectations
Jan 07
5:03pm ET
Amicus reports preliminary FY23 revenue $399.4M, consensus $396.45M
Dec 25
12:40am ET
Analysts’ Top Healthcare Picks: Hookipa Pharma (HOOK), Immunovant (IMVT)
Dec 24
6:17am ET
‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks
No recent news articles are available for FOLD
No recent press releases are available for FOLD
FOLD Financials
Key terms
Ad Feedback
FOLD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FOLD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range